Brainsway: Insurance coverage in Washington extends coverage in OCD treatment

BrainsWay announced that a major private insurance company in Washington state will extend positive coverage applicable to Deep Transcranial Magnetic Stimulation Deep TMS for the treatment of obsessive-compulsive disorder OCD as of February 3 . This policy extension provides coverage of Deep TMS for OCD to approximately 2.2M members. The policy change also reduces major depressive disorder MDD TMS coverage criteria from four failed medication trials to only three. OCD coverage criteria is also three failed medication trials. "Over the past two years, BrainsWay has seen significant coverage expansion of Deep TMS, including reduced patient selection criteria and earlier access to treatment for both MDD and OCD patients," said Scott Blackman, Director of Market Access of BrainsWay. "This has been especially evident in the Medicare population where all Medicare administrative contractors now cover depression with only one or two failed medication trials."